DMAA (Drugs Made In America Acquisition) Long-Term Debt: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DMAA Drugs Made In America Acquisition Corp DMAA
14 GF Score
Price $10.70
! 1 Warning Sign
View Full Analysis

What is Drugs Made In America Acquisition Long-Term Debt?

Drugs Made In America Acquisition DMAA +0.09% 14 Long-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus rates DMAA with a GF Score™ of 14/100. The stock has 1 warning sign investors should review.

Drugs Made In America Acquisition's Long-Term Debt for the quarter that ended in Mar. 2026 was $0.00 Mil.

Drugs Made In America Acquisition  (NAS:DMAA) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Drugs Made In America Acquisition Long-Term Debt Related Terms

Drugs Made In America Acquisition Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Drugs Made In America Acquisition's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Drugs Made In America Acquisition Long-Term Debt Chart

Drugs Made In America Acquisition Annual Data
Trend Dec24 Dec25
Long-Term Debt
0.00 0.00

Drugs Made In America Acquisition Quarterly Data
Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
DMAA
14GF Score
Drugs Made In America Acquisition Corp DMAA
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.00 Mil mean?
Drugs Made In America Acquisition (DMAA) has a Long-Term Debt of $0.00 Mil as of Mar. 2026.
Is Drugs Made In America Acquisition's Long-Term Debt too high?
Drugs Made In America Acquisition's current Long-Term Debt is $0.00 Mil. Overall, Drugs Made In America Acquisition has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Drugs Made In America Acquisition's Long-Term Debt compare to PLMK and TRGS?
Drugs Made In America Acquisition's Long-Term Debt of $0.00 Mil can be compared against companies in the Diversified Financial Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Diversified Financial Services company?
A good Long-Term Debt depends on the Diversified Financial Services industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Drugs Made In America Acquisition's current Long-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Drugs Made In America Acquisition stock overvalued right now?
Drugs Made In America Acquisition (DMAA) has a current Long-Term Debt of $0.00 Mil. The current Long-Term Debt is $0.00 Mil. Drugs Made In America Acquisition's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Drugs Made In America Acquisition (DMAA), the current Long-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Drugs Made In America Acquisition Business Description

Address 420 Lexington Avenue, Suite 1402, New York, NY, USA, 10170
Drugs Made In America Acquisition Corp is a blank check company.
14GF Score

Get the complete analysis for DMAA

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.70
Price